Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.47
+0.13 (+2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-25.9M · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.0B
P/E
71.9x
↑EV/EBITDA
11.6x
↓ROE
1.4%
↑Gross Margin
20.9%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
—
FCF margin
0.5%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.20B · net income $53.9M · FCF $16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.20B | $3.20B | $3.28B | $3.19B | $2.67B |
| Net Income | $53.9M | $53.9M | $40.4M | $106.2M | $105.3M |
| EBITDA | $231.6M | $231.6M | $203.1M | $299.8M | $252.4M |
| EPS | 0.09 | 0.09 | 0.07 | 0.21 | 0.21 |
| Gross Margin | 20.9% | 20.9% | 18.5% | 20.0% | 19.8% |
| Operating Margin | 1.1% | 1.1% | 1.2% | 3.0% | 2.3% |
| Net Margin | 1.7% | 1.7% | 1.2% | 3.3% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.01 | 0.00 |
| Current Ratio | 3.93 | 3.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.3M | $16.3M | $-47.4M | $-25.9M | $-49.1M |
| Returns | |||||
| ROE | 1.4% | 1.4% | 1.1% | 3.3% | 3.5% |
| Valuation | |||||
| P/E | 71.89 | 71.89 | 92.38 | 38.11 | 37.63 |
| EV/EBITDA | 11.65 | 11.65 | 10.59 | 8.48 | 9.79 |
| P/B | 1.07 | 1.07 | 0.98 | 1.25 | 1.32 |
| Growth & Yield | |||||
| Revenue Growth | -2.6% | -2.6% | 2.7% | 19.6% | — |
| EPS Growth | 27.1% | 27.1% | -67.6% | 0.9% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
87.8%
EPS terminal req.
$0.57
Spread vs growth
-60.7%
5Y implied EPS CAGR
51.6%
EPS terminal req.
$0.69
Spread vs growth
-24.5%
10Y implied EPS CAGR
29.1%
EPS terminal req.
$1.12
Spread vs growth
-2.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.9%
Start / end P/E
98.2x → 74.6x
EPS bridge
0.07 → 0.09
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.